Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siEphA2-LNP
- Development stage
- Preclinical
- Lead developer
- Methodist Hospital Research Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
siEphA2-LNP is an experimental lipid nanoparticle (LNP) formulation encapsulating small interfering RNA (siRNA) designed to target and silence the expression of Ephrin type-A receptor 2 (EphA2). EphA2 is a receptor tyrosine kinase that is frequently overexpressed in various cancers, including breast and prostate cancers, and plays a critical role in tumor progression, metastasis, and therapy resistance. Developed by researchers at the Houston Methodist Research Institute, Texas A&M University, and the University of Louisville, siEphA2-LNP is being investigated for the treatment of breast cancer liver metastases (BCLM) and triple-negative breast cancer (TNBC). By delivering EphA2-targeting siRNA, the formulation downregulates EphA2 expression, which modulates the tumor microenvironment by polarizing tumor-associated macrophages from an immunosuppressive M2 phenotype to a pro-inflammatory, anti-tumorigenic M1 phenotype, thereby reducing tumor burden and enhancing therapeutic efficacy.
- Other names
- EphA2 siRNA-loaded lipid nanoparticlesEphA-2 siRNA-loaded lipid nanoparticlesEphA 2 siRNA-loaded lipid nanoparticlessiRNA EphA2 loaded lipid nanoparticles
02
Targets
EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on siEphA2-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siEphA2-LNP.